Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 22Immunoglobulin Light-chain Amyloidosis 4Waldenstrom Macroglobulinemia 3Recurrence 2Lymphoma, T-Cell, Peripheral 2Smoldering Multiple Myeloma 1Sarcoma, Kaposi 1Proteostasis Deficiencies 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm, Residual 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Amyloidosis 1

Interventions

Lenalidomide 7Dexamethasone 5daratumumab 4Calcium Dobesilate 4dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Curcumin 3isatuximab 2iberdomide 2Leflunomide 2pomalidomide 1poly ICLC 1piperine 1pembrolizumab 1ixazomib 1fludarabine phosphate 1fludarabine 1citarinostat 1Watchful Waiting 1Urination 1Stem Cell Transplantation 1Resistance Training 1Propranolol 1Probiotics 1Peripheral Blood Stem Cell Transplantation 1PVX-410 vaccine 1Observation 1Metformin 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Smoldering Multiple Myeloma × ixazomib × 1 year × Clear all
NCT02916771 2025-08-11

Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

Dana-Farber Cancer Institute

Phase 2 Completed
61 enrolled 12 charts
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡